Agency Forms Undergoing Paperwork Reduction Act Review, 66533-66534 [E6-19263]

Download as PDF Federal Register / Vol. 71, No. 220 / Wednesday, November 15, 2006 / Notices Diseases (NCID)—Centers for Disease Control and Prevention (CDC). Background and Brief Description The proposed project will focus on travelers visiting friends and relatives (VFR) in Latin America. An estimated 44% of all international travel is VFR related. Although multiple definitions exist, VFR travelers typically refer to those who were born in a resource-poor country, now living in a resource-rich country, and returning to their country of birth to visit friends and relatives. VFR travelers have received particular attention recently for being at higher risk than other travel groups for acquiring communicable diseases during visit to their home countries. However, there are few studies that 66533 theory-driven infectious diseases prevention messages, both pre-travel and during travel, that will be specific to subpopulations of travelers (VFR versus non-VFR). Expected outcomes of targeted messaging include reducing • The burden of illness among travelers, • the importation of communicable diseases into the U.S., and • the global spread of infectious diseases. The proposed study will provide departing airport passengers with a selfadministered 35-item questionnaire and a follow-up telephone questionnaire four weeks after their return. There is no cost to the respondent other than their time. characterize and explore this health disparity between VFR and non-VFR travelers. The proposed study would be the first to focus on travel-related health risks in U.S resident VFR and non-VFR travelers to Latin America. The study objectives are to characterize and understand the health disparities between VFR and non-VFR travelers to Latin America by comparing (1) pre-travel health preparations, (2) perceived susceptibility and severity to travelrelated communicable diseases, (3) health-risk behaviors during travel, and (4) compliance with prevention measures during travel. Knowledge gained from this study will enable CDC to develop targeted, ESTIMATED ANNUALIZED BURDEN HOURS Number of responses/ respondent Number of respondents Respondents Average burden/response (in hours) Total burden hours Screener Interview ........................................................................................... Self-Administered ............................................................................................. Telephone Interview ........................................................................................ 2800 700 490 1 1 1 5/60 15/60 10/60 233 175 82 Total .......................................................................................................... ........................ ........................ ........................ 490 Dated: November 8, 2006. Joan F. Karr, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E6–19262 Filed 11–14–06; 8:45 am] comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice. BILLING CODE 4163–18–P Proposed Project National Disease Surveillance Program I—Case Reports—Revision— (OMB No. 0920–0009), National Center for Infectious Diseases (NCID), Centers for Disease Control and Prevention (CDC). DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–07–0009] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written Tularemia, Typhoid Fever, and Viral Hepatitis. Tularemia and MethicillinResistant Staphylococcus aureaus (MRSA) are new additions to this submission. Case report forms from state and territorial health departments enable CDC to collect demographic, clinical, and laboratory characteristics of cases of these diseases. This information is used to direct epidemiologic investigations, identify and monitor trends in reemerging infectious diseases or emerging modes of transmission, to search for possible causes or sources of the diseases, and develop guidelines for prevention and treatment. The data collected will also be used to recommend target areas most in need of vaccinations for selected diseases and to determine development of drug resistance. Because of the distinct nature of each of the diseases, the number of cases reported annually is different for each. There is no cost to respondents other than their time. The total annual burden hours are 13,371. Background and Brief Description Formal surveillance of 19 separate reportable diseases has been ongoing to meet the public demand and scientific interest in accurate, consistent, epidemiologic data. These ongoing disease reports include: Active Bacterial Core Surveillance (ABCs), CreutzfeldtJakob Disease(CJD), Cyclospora, Dengue, Hantavirus, Idiopathic CD4+Tlymphocytopenia, Kawasaki Syndrome, Legionellosis, Lyme disease, Malaria, Plague, Q Fever, Reye Syndrome, Tickborne Rickettsial Disease, Trichinosis, rmajette on PROD1PC67 with NOTICES1 ESTIMATE OF ANNUALIZED BURDEN HOURS Number of respondents Form ABCs .............................................................................................................. ABCs Invasive MRSA .................................................................................... VerDate Aug<31>2005 15:00 Nov 14, 2006 Jkt 211001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 329 18 Number responses/ respondent 21 256 E:\FR\FM\15NON1.SGM 15NON1 Total responses 6,909 4,608 Hrs/response 10/60 10/60 66534 Federal Register / Vol. 71, No. 220 / Wednesday, November 15, 2006 / Notices ESTIMATE OF ANNUALIZED BURDEN HOURS—Continued Number of respondents Form CJD ................................................................................................................ Cyclosporiasis ................................................................................................ Dengue Case Investigation ........................................................................... Hantavirus Pulmonary Syndrome .................................................................. Idiopathic CD4+T-lymphocytopenia ............................................................... Kawasaki Syndrome ...................................................................................... Legionellosis Case Report ............................................................................. Lyme Disease Report .................................................................................... Malaria Case Surveillance Report ................................................................. Plague Case Investigation Report ................................................................. Q Fever .......................................................................................................... Reye Syndrome Case Surveillance Report ................................................... Tick-borne Rickettsial Disease Case Report ................................................. Trichinosis Surveillance Case Report ............................................................ Tularemia ....................................................................................................... Typhoid Fever Surveillance Report ............................................................... Viral Hepatitis Case Record .......................................................................... Dated: November 8, 2006. Joan F. Karr, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E6–19263 Filed 11–14–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention rmajette on PROD1PC67 with NOTICES1 Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Assessment of Proposed Revisions to the Youth Tobacco Survey: Impact on Measures of Youth Tobacco Use, Request for Application Number (RFA) DP07–001 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting of the aforementioned Special Emphasis Panel. Time and Date: 2:30 p.m.–5:30 p.m., December 12, 2006 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of research grant applications in response to RFA DP07–001, ‘‘Assessment of Proposed Revisions to VerDate Aug<31>2005 15:00 Nov 14, 2006 Jkt 211001 20 55 55 46 10 55 23 52 55 55 55 50 55 55 55 55 55 the Youth Tobacco Survey: Impact on Measures of Youth Tobacco Use.’’ For Further Information Contact: Brenda Colley Gilbert, Acting Director, Office of Extramural Research, National Center for Chronic Disease Prevention and Health Promotion, 4770 Buford Highway, NE., MS K92, Atlanta, GA 30341, telephone 770.488.8390. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: November 8, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–19234 Filed 11–14–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Occupational Health and Safety Research, Member Conflict, Program Announcement (PA) 04–038 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting of the aforementioned Special Emphasis Panel. PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Number responses/ respondent Total responses 2 10 182 3 2 8 11.7 385 20 0.20 1 1 18 .45 2.2 6 200 40 550 10,010 138 20 440 269 20,020 1,100 11 55 50 990 25 121 330 11,000 Hrs/response 20/60 15/60 15/60 20/60 10/60 15/60 20/60 10/60 15/60 20/60 10/60 20/60 10/60 20/60 20/60 20/60 25/60 Time and Date: 1 p.m.–2:30 p.m., November 28, 2006 (Closed). Place: Teleconference. National Institute for Occupational Safety and Health, CDC, 2400 Century Parkway, NE., Atlanta, GA 30345. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of research grant applications in response to ‘‘Occupational Health and Safety Research,’’ PA 04–038. For Further Information Contact: Charles N. Rafferty, Ph.D., Designated Federal Official, 100 Clifton Road, Mailstop E–74, Atlanta, GA 30333, telephone (404) 498–2582. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: November 8, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6–19235 Filed 11–14–06; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\15NON1.SGM 15NON1

Agencies

[Federal Register Volume 71, Number 220 (Wednesday, November 15, 2006)]
[Notices]
[Pages 66533-66534]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-19263]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-07-0009]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-5960 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.

Proposed Project

National Disease Surveillance Program I--Case Reports--Revision--
(OMB No. 0920-0009), National Center for Infectious Diseases (NCID),
Centers for Disease Control and Prevention (CDC).

Background and Brief Description

Formal surveillance of 19 separate reportable diseases has been
ongoing to meet the public demand and scientific interest in accurate,
consistent, epidemiologic data. These ongoing disease reports include:
Active Bacterial Core Surveillance (ABCs), Creutzfeldt-Jakob
Disease(CJD), Cyclospora, Dengue, Hantavirus, Idiopathic CD4+T-
lymphocytopenia, Kawasaki Syndrome, Legionellosis, Lyme disease,
Malaria, Plague, Q Fever, Reye Syndrome, Tick-borne Rickettsial
Disease, Trichinosis, Tularemia, Typhoid Fever, and Viral Hepatitis.
Tularemia and Methicillin-Resistant Staphylococcus aureaus (MRSA) are
new additions to this submission. Case report forms from state and
territorial health departments enable CDC to collect demographic,
clinical, and laboratory characteristics of cases of these diseases.
This information is used to direct epidemiologic investigations,
identify and monitor trends in reemerging infectious diseases or
emerging modes of transmission, to search for possible causes or
sources of the diseases, and develop guidelines for prevention and
treatment. The data collected will also be used to recommend target
areas most in need of vaccinations for selected diseases and to
determine development of drug resistance.
Because of the distinct nature of each of the diseases, the number
of cases reported annually is different for each. There is no cost to
respondents other than their time. The total annual burden hours are
13,371.

Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number
Form Number of responses/ Total Hrs/response
respondents respondent responses
----------------------------------------------------------------------------------------------------------------
ABCs............................................ 329 21 6,909 10/60
ABCs Invasive MRSA.............................. 18 256 4,608 10/60

[[Page 66534]]

CJD............................................. 20 2 40 20/60
Cyclosporiasis.................................. 55 10 550 15/60
Dengue Case Investigation....................... 55 182 10,010 15/60
Hantavirus Pulmonary Syndrome................... 46 3 138 20/60
Idiopathic CD4+T-lymphocytopenia................ 10 2 20 10/60
Kawasaki Syndrome............................... 55 8 440 15/60
Legionellosis Case Report....................... 23 11.7 269 20/60
Lyme Disease Report............................. 52 385 20,020 10/60
Malaria Case Surveillance Report................ 55 20 1,100 15/60
Plague Case Investigation Report................ 55 0.20 11 20/60
Q Fever......................................... 55 1 55 10/60
Reye Syndrome Case Surveillance Report.......... 50 1 50 20/60
Tick-borne Rickettsial Disease Case Report...... 55 18 990 10/60
Trichinosis Surveillance Case Report............ 55 .45 25 20/60
Tularemia....................................... 55 2.2 121 20/60
Typhoid Fever Surveillance Report............... 55 6 330 20/60
Viral Hepatitis Case Record..................... 55 200 11,000 25/60
----------------------------------------------------------------------------------------------------------------

Dated: November 8, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E6-19263 Filed 11-14-06; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.